HOME >> MEDICINE >> NEWS
Clarifying controversy in multiple sclerosis

Multiple sclerosis (MS) is a crippling autoimmune disease of the central nervous system (CNS) in which the protective nerve cell coating called myelin is damaged. Although uncontrolled CNS inflammation by immune cells called microglia (MG) and production of the protein TNF-alpha are considered important causes of demyelination and loss of nerve (neuron) function in MS, there is evidence to suggest that a controlled inflammatory response may actually restore damaged myelin and nerve function. Now, in a study appearing online on March 23 in advance of print publication in the April issue of the Journal of Clinical Investigation, researcher Michal Schwartz and colleagues at the Weizmann Institute of Science in Israel help clarify the controversy by reporting that it is the mechanism by which the MGs are activated that determines whether they are destructive or protective. Using both mouse and rat animal models of MS, the authors show that production by immune cells known as helper T cells of small amounts of a proinflammatory protein called IFN-gamma or production of an anti-inflammatory protein IL-4 could stimulate MGs to support nerve cell survival. In contrast, the researchers show that MGs fail to protect neurons when they are exposed to high doses of IFN-gamma, because high levels of IFN-gamma stimulate the MGs to produce TNF-alpha. The results demonstrate that the helper T cells can have direct control over MG action, stimulating them to either support or destroy nerve cell function through production of IL-4, and suggest that stimulation of MGs with IL-4 may help in MS clinical recovery.


'"/>

Contact: Brooke Grindlinger
press_releases@the-jci.org
212-342-9006
Journal of Clinical Investigation
23-Mar-2006


Page: 1

Related medicine news :

1. Drug-eluting stent controversy explored in the American Heart Hospital Journal
2. IOM report should end nevirapine controversy, HIVMA says
3. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
4. University hospitals wins multiple national IT awards for electronic patient data bank
5. Revlimid data presented at ASCO stands to change the way physicians treat multiple myeloma
6. Glucosamine-like supplement inhibits multiple sclerosis, type 1 diabetes
7. Testosterone may help men with multiple sclerosis
8. Mayo Clinic Cancer Center researcher finds mold by-product kills multiple myeloma
9. Mayo Clinic Cancer Center -- individualizing treatment for multiple myeloma patients
10. New GreeneChip identifies multiple pathogens rapidly and accurately
11. GreeneChip -- New diagnostic tool that rapidly and accurately identifies multiple pathogens

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/22/2017)... ... 2017 , ... On Sunday, September 24, hundreds will gather at Flo Jo ... considered the fastest woman of all time. Flo Jo passed away from complications ... the National Anthem. Mary was a contestant on the 2012 season of America’s ...
(Date:9/22/2017)... ... September 22, 2017 , ... Ecocor ... Richard Pedranti Architect (RPA), a full-service architecture firm focusing on sustainable ... Solsken Line of Model Homes . Independently, Ecocor and RPA have extensive experience ...
(Date:9/22/2017)... ... September 22, 2017 , ... SABRE is pleased to ... Molli C., a graduate student from Sonora, California, who will begin her studies ... Thomas University in Miami, Florida, was selected from a pool of more than ...
(Date:9/22/2017)... ... September 22, 2017 , ... “Cursed ... of an obligatory tithe, and the freedom experienced when breaking free from this ... published author, Lysa M. Harrison. , Published by Christian Faith Publishing, Lysa M. ...
(Date:9/22/2017)... ... 2017 , ... "Success Files," a short- and long-form documentary ... a disease estimated to affect the lives of more than 5 million Americans ... a leading voice in the fight for cure and research into the disease, ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... NeuroRx, a clinical stage biopharma company developing the ... has been granted Fast Track status by the US Food ... HCl) followed by NRX-101 (D-cycloserine + lurasidone). The company will ... sequential therapy targeting patients who are admitted to Emergency Departments ... ...
(Date:9/5/2017)... -- Xyntek Inc. has announced another milestone in their continued growth and success of ... growing demands of customer engagements regionally.  ... Midwest office is located at 318 West Adams Street, Suite 1528, Chicago, IL ... Xyntek's recently opened Midwest ... In ...
(Date:9/5/2017)... JERUSALEM , Sept. 5, 2017 Oramed Pharmaceuticals ... www.oramed.com ), a clinical-stage pharmaceutical company focused on the ... it has successfully concluded its meeting with the U.S. ... novel oral insulin formulation. ... that the regulatory pathway for submission of ORMD-0801, would ...
Breaking Medicine Technology:
Cached News: